Interleukin 15 Induces Endothelial Hyaluronan Expression In Vitro and Promotes Activated T Cell Extravasation through a CD44-dependent Pathway In Vivo

By Pila Estess, Animesh Nandi, Mansour Mohamadzadeh, and Mark H. Siegelman

From the Laboratory of Molecular Pathology, Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas 75235-9072

Summary

T cell recruitment to extralymphoid tissues is fundamental to the initiation and perpetuation of the inflammatory state during immune and autoimmune responses. Interleukin (IL)-15 is a proinflammatory cytokine whose described functions largely overlap with those of IL-2. The latter is attributable in large part to its binding of the heterotrimeric receptor that contains the β and γ chains of the IL-2R in combination with an unique IL-15Rα chain. However, unlike IL-2, IL-15 and its receptor have a wide tissue and cell type distribution, including endothelial cells. Here, we examine the effect of IL-15 on hyaluronan expression by endothelial cells, and investigate its role in vivo in promoting the extravasation of antigen-activated T cells through a CD44-dependent pathway. The expression of hyaluronan on primary endothelial cells and microvascular endothelial cell lines is induced by IL-15, whereas IL-2 has no such activity. Moreover, intraperitoneal administration of IL-15 or TNF-α in the absence of other exogenous proinflammatory stimuli allows the extravasation of superantigen-stimulated T cells into this site in vivo in a CD44-dependent manner. T cell recruitment induced by IL-15 requires expression of an intact IL-2Rβ chain, indicating that IL-15 operates in this context through the traditional IL-15R. The results suggest that IL-15 can regulate endothelial cell function and thereby enable a CD44-initiated adhesion pathway that facilitates entry of activated T lymphocytes into inflammatory sites. They further demonstrate a novel role for IL-15 (distinct from any of IL-2) in regulating microvascular endothelial cell adhesive function, help to understand the role of IL-15R expression on endothelium, and further support a central position for this cytokine in orchestrating multiple sequential aspects of T cell effector function and therefore chronic inflammatory processes.

Key words: CD44 • endothelial cell • hyaluronate • interleukin 15 • lymphocyte adhesion

The specificity and regulation of leukocyte extravasation results in part from the differential expression of various types of adhesion receptors on endothelium within tissues and on leukocyte subsets, and partially from the fact that these receptors can act in sequential fashion. Our laboratory has been engaged in the description and characterization of a novel primary adhesion (rolling) interaction between the activated form of the cartilage link proteoglycan family member CD44 on lymphocytes and its major ligand, the glycosaminoglycan hyaluronan (HA)1 on endothelial cells (ECs) (1). We have shown in a mouse model that this interaction can function in an extravasation pathway that results in the egress of antigen-activated lymphocytes in an inflamed vascular bed (2, 3). We have further demonstrated that HA expression is increased on microvascular primary EC cultures and EC lines in response to proinflammatory stimuli such as TNF-α, IL-1β, and LPS in vitro. This elevated expression results in increased interactions of activated lymphocytes with endothelium under shear forces (4). These observations have led us to propose that the activated form of CD44 is induced on lymphocytes as a result of antigen stimulation, followed by release of activated cells from secondary lymphoid sites into the peripheral circulation. Activated CD44 would then function to initiate lymphocyte extravasation at sites of antigen localization or inflammation, where HA has been upregulated on the endothelium. In support of this model, circulating lymphocytes bearing

1 Abbreviations used in this paper: bPG, bovine proteoglycan; CFDA-SE, 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester; EC, endothelial cell; HA, hyaluronan; HUVEC, human umbilical vein endothelial cell; ICAM, intracellular adhesion molecule; MLN, mesenteric lymph node; RT-PCR, reverse transcription polymerase chain reaction; SA-PE, phycoerythrin-labeled Streptavidin; SEB, Staphylococcal enterotoxin B; VCAM, vascular cell adhesion molecule.
activated CD44 have been shown to be elevated during autoimmune exacerbations in both arthritis and systemic lupus erythematosus in humans (5). This finding suggests that such cells represent a pathogenically important subset of activated T cells and may serve as a reliable marker for autoimmune or other chronic inflammatory disease activity.

IL-15 is a cytokine originally identified as a T cell growth factor and described to have biological activities similar to IL-2 (6, 7). These properties include induction of T cell proliferation; potent T cell chemotaxis; costimulation of B cell growth and isotype switching; and promotion of natural killer cell growth, cytokotoxicity, and cytokine production (8). IL-15 has also been reported to inhibit apoptosis and to enhance the survival of activated T cells in vivo (9, 10).

However, unlike IL-2, IL-15 is expressed in diverse types of tissues, including skeletal muscle and kidney, as well as in a variety of cell types such as activated monocytes, fibroblasts, and keratinocytes. IL-15 generally mediates its activity through a heterotrimeric receptor consisting of a unique IL-15Rα chain in combination with the IL-2Rβ and γ chains (8). Like IL-15, the unique IL-15Rα chain has a broad tissue distribution, suggesting potential functions for this cytokine outside of the hematolymphoid system. IL-15 thus has been shown recently to have anabolic effects on skeletal muscle (11) and may serve as an angiogenic factor (12).

IL-15 has been suggested to play a role in the setting of the chronic autoimmune disease rheumatoid arthritis, particularly in the recruitment and activation of synovial T cells. This cytokine has been reported to be elevated within the synovial fluid of affected patients, and administration of IL-15 into the hind footpad of mice resulted in an enhanced mononuclear cell infiltrate, predominantly T cells, at the site of injection, although the mechanism for this was not elucidated (8, 13). Recently, in a mouse model of collagen-induced arthritis, a soluble form of the IL-15Rα chain was shown to be effective in ameliorating disease (14). This cytokine also has been shown to have clear effects on chemotaxis and migration of lymphocytes (8, 15). However, a pivotal element of inflammatory cell recruitment not previously examined for this cytokine is extravasation from the blood. Because we have defined a CD44-dependent adhesion pathway pertinent to activated T cells, it was of interest to investigate whether IL-15 has a role in the extravasation of T cells as well.

In the study presented here, we demonstrate that ECs directly respond to IL-15 in vitro with increased cell surface expression of HA and that, as with other proinflammatory stimuli (16), this responsiveness appears largely restricted to small venular endothelial sources. Moreover, in an in vivo model of peritoneal inflammation, IL-15 is sufficient to promote the extravasation of superantigen-activated T cells, and this is dependent on CD44 interactions with HA. Neither the in vitro nor the in vivo activity is induced by IL-2, suggesting this is a unique function for IL-15, although the shared receptor chain β appears to be required. These results place a function for IL-15 at the interface between the blood and vasculature, a vital position in the sequence of T cell effector processes, through regulation of CD44/HA interactions.

Materials and Methods

Chemicals and Reagents. Biotinylated bovine proteoglycan (bPG) extracted from bovine nasal cartilage (17) was provided by C. Underhill (Georgetown University School of Medicine, Washington, DC). Rostec comb HA and Staphylococcal enterotoxin B (SEB) were purchased from Sigma Chemical Co. 5- (and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE), was purchased from Molecular Probes, Inc. KM 81, a rat anti-mouse CD44 that blocks HA binding (18) and anti-mouse intracellular adhesion molecule (ICAM)-1 (clone YN1/1.7.4) were purchased from the American Type Culture Collection and anti-mouse vascular cell adhesion molecule (VCAM)-1 (clone M/K-2.7) was provided by L. K. Thorpe (University of Texas Southwestern Medical Center, Dallas, TX). Antibody was purified from tissue culture supernatants by Protein A-Sepharose column chromatography. Rat anti-mouse H-2 (clone M/1/42) was purchased from K. Fischer-Lindahl (Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX). Anti-human IL-15 was obtained from R&D Systems, Inc. Rat anti-mouse TNF-α and biotinylated anti-mouse CD62P and anti-CD62E were obtained from Pharmingen.

Human TNF-α (5 × 10^7 U/mg), murine IL-1β (2.2 × 10^7 U/mg), and human IFN-γ (10^7 U/mg) were obtained from Genzyme, Inc. Human IL-15 was obtained from R&D Systems (ED₅₀ in proliferation assay 0.5–2 ng/ml) and recombinant human IL-2 (10^7 U/ml) was obtained from the Biological Research Makers Program (Frederick, MD).

EC Culture and Stimulation. SVEC 4-10 is an SV40 transformed murine LN EC line provided by K.A. O’Connell (Johns Hopkins University School of Medicine, Baltimore, MD) (21). The TME-3H lung endothelial line was similarly derived (22) and was provided by A. Hamann (Medizinischen Klinik, Hamburg, Germany) and J. Lesley (Salk Institute, San Diego, CA). LEI is a murine lung capillary EC line derived by A. Curtis (University of Glasgow, Glasgow, UK) and was provided by P. Thorpe (University of Texas Southwestern Medical Center, Dallas, TX). Cells were maintained in RPMI 1640–high glucose, 15% FCS plus 1 mM pyruvate, 2 mM glutamine, and 50 μM β-mercaptoethanol. EC lines were taken from frozen storage and used up to a maximum of five passages. Human umbilical vein ECs (HUVEC) were obtained from S.W. Caughman (Skin Center at Emory University, Atlanta, GA) and were used upon reaching confluence or after their first or second passages. Primary LN EC (L’LN EC) cultures were made by pooling cervical and axial nodes from three animals, as described (23, 24). Organs were minced, rinsed to remove lymphocytes, treated with collagenase for 30 min at 37°C, and plated on 35-mm culture dishes in supplemented IMDM (20% FCS). These cultures at confluence showed the morphologic and phenotypic characteristics indicating >95% EC content, as previously described (1). After reaching initial confluence, cells were passage and used directly or after one additional passage to fresh plates.

For stimulation of ECs, cells were passaged 24–48 h before addition of stimuli, when cultures were subconfluent. Stimuli were added to 1 ml of culture medium as follows, except as noted in dose–response experiments: TNF-α and IFN-γ to a final concentration of 10 ng/ml; IL-2 and IL-15 to a final concentration of 50 ng/ml. Cells were maintained at 37°C in a 5% CO₂ atmosphere for 4 h, unless otherwise noted. Control cultures without exogenous stimuli were incubated in parallel in all experiments. Cells were harvested for FACScan analysis and RNA isolation by gentle pipetting after incubation with Versene (GIBCO BRL) for 5 min at 37°C. Anti–IL-15 or anti–TNF-α was included in some
EC cultures at a final concentration of 100 ng/ml. For rolling assays, ECs were grown in 35-mm Corning tissue culture dishes.

FACS

A) analysis. 5 × 10^5 cells were stained with biotin or primary antibody in 100 μl PBS/2% FCS for 30 min and then washed with 500 μl of PBS/2% FCS. PE-labeled Streptavidin (SA-P; Caltag Labs.) or goat anti–rat immunoglobulin-FITC (Caltag Labs) was added for an additional 30 min. Cells were washed and analyzed using a FACSScan™ instrument and CellQuest™ software (Becton Dickinson).

Reverse transcription PCR. Total RNA was isolated according to the manufacturer's instructions using RNeasyol (Bioteck). R reverse transcription (RT)-PCR amplification was performed as previously described (25). The following primer pairs were used: IL-2R α, 5′ CCTACAAGAACGACCCACCT/ µl of PCR product from the IL-2R α or γ reactions were hybridized in liquid phase (240 mM NaCl, 2.4 mM Tris/1 mM EDTA) with 10 μl of 32P-end-labeled internal probe (IL-2R α chain: 5′ AGCTGAGATGGAAAAGCAGACA; IL-2R γ chain: 5′ GCTCCCTGCGATGGACCTCA). PCR reactions were performed semi-quantitatively and compared with β-actin PCR amplifications run in parallel. For liquid hybridization of RT-PCR products, oligonucleotide probe was end-labeled with 32P-dCTP and T4 polynucleotide kinase. 5% (5 µl) of PCR product of the IL-2R α or γ reactions were hybridized in liquid phase (240 μM NaCl, 2.4 mM Tris/1 mM EDTA) with 10 µl of 32P-end-labeled internal probe (IL-2R α chain: 5′ AGCTGAGATGGAAAAGCAGACA; IL-2R γ chain: 5′ GCTCCCTGCGATGGACCTCA). Cycling conditions were 95°C for 90 s, and 72°C for 120 s.

Results

IL-15, But Not IL-2, Induces Increased HA Expression on Cultured ECs. IL-15 has not been reported previously to induce increased levels of adhesion molecule expression. To examine the effect of IL-15 on the level of surface HA expression, the LN-derived EC line SVEC4-10 was incubated for 4 h in the presence of IL-15, TNF-α, IL-2, or IFN-γ. Using a biotinylated form of the HA-binding proteoglycan bPG to detect cell surface HA, we found that IL-15 treatment resulted in a marked increase in the amount of surface HA expression, which was comparable to levels seen with TNF-α treatment (reference 4 and Fig. 1 A). Moreover, HA surface expression appeared selectively induced, as other endothelial adhesion molecules showed no substantial alterations in levels of expression after IL-15 treatment (Fig. 1 B), although VCAM-1 and P-selectin were both increased on this cell line after LPS treatment (data not shown). Kinetic studies further demonstrated that surface HA expression was maximal at 4 h, consistent with the time course previously demonstrated with other proinflammatory cytokines (4). In contrast to IL-15, IL-2 had no effect on the level of bPG binding on these ECs, although these two cytokines have overlapping functions in many biological systems (15). IFN-γ (Fig. 1 A) and IL-12 (4) had no effect on HA expression, as previously reported. Also, bPG staining of TNF-α-treated SVEC4-10 cells was blocked by preincubating cells with soluble HA before staining with bPG (1), indicating specificity of this reagent (17). Thus, the proin-
Figure 1. Induction of bPG staining on ECs in response to cytokine treatment. (A) Levels of cell surface HA increase following treatment of SVEC4-10 cells with TNF-α or IL-15. Cells were incubated for 4 h with TNF-α (10 ng/ml), IL-15 (50 ng/ml), IL-2 (50 ng/ml), or IFN-γ (10 ng/ml), harvested in EDTA, stained with bPG-biotin plus SA-PE, and analyzed by FACS® for bPG binding. Unstimulated cells, which constitutively express some HA, bind background levels of bPG (solid line). A treatment with TNF-α or IL-15, cells show even greater levels of staining (stippled line), whereas IL-2 has no effect. As previously shown, binding to bPG was not increased by incubation with IFN-γ (4). Baseline staining of SVEC4-10 cells with SA-PE alone is indicated by the dashed line in the TNF-α panel. Preincubating TNF-α-treated cells with soluble HA reduced bPG staining to near background levels (heavy line), (B) Expression of ICAM-1, VCAM-1, P-selectin, and E-selectin by SVEC4-10 cells before (stippled line) and after (solid line) IL-15 treatment. (C) TME-3H3, 1LN EC, LEII, and HUVEC cells were treated with human IL-15 (10 ng/ml), harvested in EDTA, stained with bPG-biotin plus SA-PE, and analyzed by FACS® for bPG binding. Unstimulated cells, which constitutively express some HA, bind background levels of bPG (solid line). After treatment with TNF-α or IL-15, cells show even greater levels of staining (stippled line), whereas IL-2 has no effect. As previously shown, binding to bPG was not increased by incubation with IFN-γ (4). Baseline staining of SVEC4-10 cells with SA-PE alone is indicated by the dashed line in the TNF-α panel. Preincubating TNF-α-treated cells with soluble HA reduced bPG staining to near background levels (heavy line), (D) Dose–concentration curves, as shown. Results are reported as the mean fluorescence intensity (MFI) of cells after staining with bPG-biotin plus SA-PE, as determined by FACS® analysis. IL-2 had no effect on HA expression by SVEC4-10 cells, even at 200 ng/ml, whereas IL-15 had a dose-dependent effect on surfaces of HA, with changes seen at 10 ng/ml. Data shown are the mean ± SD from three separate experiments.

flammary cytokine IL-15 acts as a potent and selective regulator of surface HA expression.

To compare the effects of IL-15 and contrast them with IL-2 on a variety of EC sources, we used several other EC lines, including another SV40-transformed murine LN line (TME-3H3), early passages of primary murine LN ECs (1LN EC), a murine lung capillary EC line (LEII), and HUVECs. Results are shown in Fig. 1 C, where it can be seen that IL-15 increases HA expression on the other two LN-derived ECs, also derived from microvascular venular endothelium. In contrast, IL-15 had no effect on expression of HA by the lung capillary line LEII or by HUVECs. This is consistent with our prior results, which indicate that ECs derived from microvenular sources, where leukocyte trafficking predominantly occurs, selectively exhibit cytokine inducible HA expression (4). In contrast to the effects of IL-15, treatment with IL-2 had no effect on HA expression in any of the ECs tested.

To determine the dose responsiveness of SVEC cells to IL-15 and whether IL-2 has any influence at higher concentrations, dose–response curves were performed. Evaluation of the response to IL-2 over a range of concentrations indicated that this cytokine had no effect on HA expression levels even at the highest concentrations used (Fig. 1 D). The maximal response to human IL-15 was attained at 50 ng/ml. The dose–response curves suggest that IL-15 is effective in a concentration range comparable with those seen in other cytokines (4). In contrast, murine IL-2 failed to have any effect at concentrations as high as 400 ng/ml (data not shown). Thus, unlike many of its other described functions, IL-15 behaves in a manner completely distinct from IL-2 with regard to endothelial HA induction.

ECs Produce the IL-2R β and γ Chain and IL-15R α Chain, But Not the IL-2R α Chain. We next addressed the expression of IL-15R and IL-2R chains in these ECs. RNA was prepared from SVEC4-10, TME-3H3, LEII, or 1LN EC to examine these for the expression of IL-2R β and γ chain message, the IL-2R α chain, and IL-15R α chain. As seen in Fig. 2 A, agarose gel analysis of RT-PCR products revealed significant expression in unstimulated ECs of both the IL-2R β and the IL-15R α chains. Since ECs did not make sufficient levels of either the IL-2R α or γ chains for direct detection by ethidium staining, the PCR products for these reactions were further analyzed by hybridization to specific radiolabeled internal oligonucleotide probes. When the IL-2R γ chain RT-PCR product was hybridized in liquid phase to a 32P-labeled γ chain probe, a band of the appropriate molecular weight (573 bp) was observed (Fig. 2 B). However, similar analysis of the IL-2R α chain RT-PCR product gave no signal in any of the EC-derived RNAs (Fig. 2 C), although the control IL-2-stimulated CTLL cells did show an appropriate positive signal. Thus, ECs express all three chains of the IL-15 cytokine receptor, but lack the unique α chain specific to the IL-2R, consistent with the relative pattern of induction of HA by these two cytokines. It is notable that, similar to HUVECs, LEII expresses mRNA for all IL-15R chains, yet these two EC lines are not induced to express increased HA (Fig. 1 C). This sug-
suggestion that differences either in receptor protein expression or downstream signaling events in these cells account for their IL-15 unresponsiveness. Thus, IL15Rα expression appears not to be sufficient for responsiveness to IL-15.

Induction of Elevated Endothelial Surface HA Expression Results in Increased Rolling Interactions of SEB-activated T Cells under Shear Stress Conditions. We have previously demonstrated that the increases in HA induced by proinflammatory stimuli are sufficient to markedly enhance rolling interactions of the clonal T cell line, BW5147, under laminar flow analysis (4).

In addition, we have shown that TCR signaling through conventional antigen or the superantigen SEB results in the conversion of CD44 to its activated form. With SEB stimulation, this activation of CD44 occurs selectively on the SEB-stimulated (Vβ8) subset of T cells (2). To determine whether the levels of HA induced on ECs by IL-15 and TNF-α had sufficient physiologic consequences to significantly alter CD44-dependent rolling interactions, normal peripheral LN T cells were stimulated in vitro with SEB and subjected to laminar flow on unstimulated ECs and ECs stimulated with IL-15 or TNF-α. Both SVEC4-10 and TME-3 cells were used in a parallel plate adhesion assay after 24 h treatment with either cytokine, when complete confluence and maximal HA expression of the monolayer was assured. Fig. 3 shows that on both EC lines induction with either IL-15 or TNF-α increased the number of rolling cells four- to fivefold over that seen on unstimulated ECs, although the cell density and viability of the monolayers were equivalent. Furthermore, blocking anti-CD44 antibody specifically inhibited rolling by >80%, suggesting VLA-4/very late antigen (VLA)-4 or other interactions do not substantially contribute to rolling under these conditions. Unactivated T cells exhibited minimal rolling on treated ECs. Thus, the changes in HA levels measured by flow cytometry are sufficient for altering the EC capacity to support CD44-dependent tethering and rolling interactions under shear stress for normal activated T cells.

Intraperitoneal administration of IL-15 results in CD44-dependent recruitment of A divided T cells into the peritoneal cavity. Previous analysis has demonstrated that SEB, which specifically activates the well-represented Vβ8-bearing T cells, induces peritoneal inflammation that results in CD44-mediated recruitment of superantigen-activated T cells into the inflamed site (3). To directly assess the ability of IL-15 to generate an inflamed site similarly receptive to the CD44/HA extravasation pathway, short-term homing assays were performed using cytokines alone as the inflammatory stimulus. Lymphocytes expressing activated CD44 were generated in vivo by intraperitoneally injecting donor mice with SEB (3). 20 h later, MLN cells were isolated, washed, and labeled with CFDA-SE. The fluorescent cells were then injected intravenously into recipient mice that had received an intraperitoneal injection of cytokine(s) or SEB (positive control) 20 h previously. 2 h after intravenous injection of

Figure 2. Endothelial cells express RNA for the IL-15R but not for IL-2R. (A) RT-PCR amplification of RNA from untreated 1LN EC, SVEC4-10, TME-3H3, and LEII cells. Amplification was done with primers specific for the murine IL-2R β chain and the IL-15Rα chain as shown. For comparison, results of amplification of β-actin RNA run in parallel with the IL-15Rα chain are shown in the bottom panel. RT-PCR amplification indicates that the primary ECs and the three EC lines make detectable levels of RNA for each of the chains. (B) Autoradiogram of the RT-PCR product resulting from amplification with primers specific for the mouse IL-2Rγ or IL-2Rα chains. RT-PCR product was hybridized in liquid phase with IL-2Rγ- or α-specific 32P-labeled oligonucleotide probes internal to the primer pairs used for amplification; hybridized sample was separated from radiolabeled probe by acrylamide gel electrophoresis and visualized by autoradiography. IL-2Rγ-specific product is clearly visible in all cells tested, whereas IL-2α-specific product was seen only in the IL-2Rα control cell line CTLL.

Figure 3. Rolling of SEB-activated LN T cells on TNF-α- or IL-15-treated SVEC4-10 and TME-3H3 monolayers. Cells were applied to feed solution already equilibrated under flow at a wall shear stress of 2.0 dynes/cm² and perfused over EC monolayers in the parallel plate flow assay. Rolling was analyzed as described above and the number of cells/mm² per min rolling across each monolayer was determined. For blocking, KM81 anti-CD44 or anti-H-2 was added to the T cell suspension before their introduction in the flow system. Rolling of SEB-activated T cells on TNF-α- and IL-15-treated ECs was significantly reduced compared with untreated ECs (P < 0.005) and TME3 (P < 0.001), and anti-CD44 significantly reduced rolling numbers compared with those on IL-15 treated ECs (P < 0.001).
donor cells, peritoneal exudate was collected from recipient mice by peritoneal lavage and samples were analyzed cytofluorometrically for CFDA (green) fluorescence to identify cells that had trafficked to the site. As seen in Fig. 4 A, when SEB-activated MLN cells were given to IL-15- or TNF-α-treated recipients, significant extravasation of cells into the peritoneum occurred. This was comparable to the levels of emigration obtained in SEB-treated recipients. The migration of donor cells into IL-15- or TNF-α-treated sites was dependent upon activated CD44, since coadministration of an HA-blocking anti-CD44 antibody at the time of donor cell transfer inhibited the transit of cells from blood into the peritoneal cavity. Isootype control-matched anti-H-2 antibody did not inhibit cell migration. Moreover, magnetic bead depletion of Vβ8-bearing cells, the predominant lymphocyte population activated by SEB, completely ablated emigration to the site, whereas depletion of the equally well-represented non-SEB-responsive Vβ14 population did not. This indicated that, as with SEB (3), it is the activated T cells that emigrate. In contrast, when SEB-activated donor cells were transferred to mice that had received intraperitoneal IL-2, IFN-γ, or IL-1β, no significant emigration was detected. Injection of unactivated donor cells from PBS-treated animals also did not result in extravasation into the peritoneal cavities of IL-15-treated recipient mice. Giving optimal amounts of IL-15 and TNF-α together did not increase migration, indicating that maximal recruitment is achieved with either cytokine alone. This further suggests that optimal HA expression is attained with either of these treatments independently. Thus, TNF-α and IL-15, but not IL-2 or IFN-γ appear to alter the local vascular bed such that it is receptive to CD44-mediated extravasation. These results correlate well with our findings of HA regulation in vitro using the same cytokines, and suggest that the in vivo observations result from local changes in endothelial HA induced by the administered cytokine. Representative two-color immunofluorescence plots of cells recovered from the peritoneal cavity of an IL-15-treated mouse are shown in Fig. 4 B. 100,000 events were collected for each sample, and those cells with green (CFDA) fluorescence in the sec-

| Donor cells | Recip mice | mAb |
|-------------|------------|-----|
| SEB         | SEB        |     |
| PBS         | IL-15      |     |
| SEB         | IL-15      |     |
| SEB         | IL-15      | αCD44 |
| SEB         | IL-15      | αH-2 |
| VBβ8 dep    | IL-15      |     |
| SEB         | IL-2       |     |
| SEB         | TNFα       | αCD44 |
| SEB         | IL-15+TNFα |     |
| SEB         | IFNγ       |     |
| SEB         | IL-1β      |     |

Figure 4. Intraperitoneal cytokine treatment allows CD44-dependent short-term homing of SEB-activated T cells into inflamed mouse peritoneal cavities. (A) CFDA-labeled MLN cells from SEB- or PBS-treated mice were injected intravenously into recipient mice that had received an intraperitoneal injection of SEB or cytokines 20 h earlier. Cells from donor mice were injected without antibody, with HA-blocking anti-CD44 mAb (KM81), or with isootype-matched control anti-H-2 mAb. 2 h after injection, peritoneal cavities of recipient mice were washed and recovered cells were analyzed by FACS® for CFDA fluorescence. Data are shown as the number of fluorescent cells/100,000 total cells analyzed and represent the mean ± SEM from three separate experiments (three mice/group per experiment). (B) Representative analysis of cells recovered from the peritoneal cavity of an IL-15 recipient mouse. CFDA+ cells exhibit green fluorescence and are visible in the lower right hand quadrant. As shown in the right hand panel, anti-CD44 treatment of the recipient animal blocks the emigration of CFDA+ cells into the peritoneal cavity. 100,000 total events were collected. (C) Time course of induction of inflamed peritoneal cavities after cytokine treatment for short-term homing of SEB-activated T cells. CFDA-labeled mesenteric LN cells from SEB-treated mice were injected intravenously into either TNF-α, IL-15-, or IL-2-treated recipients at varying time points after cytokine administration. Cells were recovered and analyzed as in A. No peritoneal accumulation of fluorescent cells is seen when injected at early time points after TNF-α or IL-15 administration (~6 h); however, significant numbers of fluorescent cells are seen when transferred ~16 h after cytokine treatment. No peritoneal accumulation of fluorescent cells is seen at any time point in IL-2 injected mice. Data are shown as the number of fluorescent cells/100,000 cells analyzed and represent the mean values ± SEM from at least three experiments (three mice/group per experiment).
ond to third decade are scored as positive (donor derived). K M 8 1 a n t i - C D 4 4 blocks the traffic of C F D A - l a b e l e d c e l l s into the recipient peritoneal cavity (Fig. 4 B, right).

Although IL-15 and TNF-α both induce HA and result in trafficking of cells bearing activated CD44 into the treated site, it was possible that the kinetics of their in vivo effects differed. In addition, results with IL-2 could potentially have been different at time points other than 20 h after treatment if, for example, the timing of HA induction was altered. To address these issues, we conducted short-term homing experiments injecting donor cells at varying time points after cytokine administration to recipient animals. With both IL-15 and TNF-α, no significant migration of cells into the peritoneal cavity was seen until 16 h after cytokine injection (Fig. 4 C), and both cytokines resulted in similar kinetics. Moreover, no significant recruitment into the peritoneal cavities of IL-2-injected animals was seen at any time point.

IL-15 Induced Short-term Homing Is Dependent on the Traditional Heterotrimeric IL-15R. An alternate IL-15R unrelated to IL-2R chains is used by mast cells for their IL-15 responsiveness (28). To determine whether the conventional IL-15R is required for CD44-dependent activated T cell extravasation in vivo, IL-2R β-deficient mice (β−/−) were examined for their ability to support IL-15-induced trafficking to the peritoneum in the short-term homing model. When SEB-activated normal MLN donor cells were transferred intravenously into β−/− recipients treated intraperitoneally 20 h previously with IL-15, there was no subsequent accumulation of CFDA-labeled cells in the recipient peritoneal cavities (Fig. 5). However, when cells were transferred into β−/− recipients treated intraperitoneally with SEB or TNF-α, homing into the peritoneal cavity occurred at levels similar to those seen in wild-type recipients. Thus, the requirement for IL-2R β expression in the recipient tissues indicates that the IL-15 effect is dependent on expression of an intact traditional IL-15R. In addition, the inflammatory recruitment induced by SEB or TNF-α administration can occur in the absence of IL-15R interactions. These data suggest that the endothelial change(s) induced by TNF-α are intact in these animals and are independent of IL-15 pathways.

IL-15 and TNF-α Induce HA Expression Indepen dently. It has been reported that TNF-α production in rheumatoid arthritis is mediated at least in part by IL-15 (29). In addition, some ECs are known to produce IL-15 at basal levels (30). We therefore investigated the possibility that TNF-α or IL-15 induction of endothelial HA occurred indirectly through the alternate cytokine and the resulting autocrine feedback mechanism occurred through the respective receptor. Cells were cultured as described above with IL-15 or TNF-α, either with or without the inclusion of anticytokine antibody. As illustrated in Fig. 6 A, the inclusion of anti-IL-15 antibody in TNF-α-stimulated EC cultures had no effect on the induction of HA. Likewise, the inclusion of anti-TNF-α antibody in IL-15-stimulated EC cultures had no effect on its induction of HA. Each antibody effectively blocked HA stimulation in control cultures (i.e., IL-15/anti-IL-15; TNF-α/anti-TNF-α). Together, the data suggest that IL-15 does not cause increased HA expression by increasing levels of TNF-α, nor does TNF-α result in increased HA expression by affecting levels of IL-15. Thus, at least two independent cell surface receptor pathways can result in changes in HA expression.

Although IL-15 and TNF-α effects were clearly independent when using isolated ECs in vitro, it was of further interest to examine this issue in vivo using the short-term homing assay, where cytokines may derive from additional hematolymphoid or stromal cells within the peritoneum. Therefore, IL-15 or TNF-α was introduced intraperitoneally as above but in the presence or absence of blocking anticytokine antibody. As seen in Fig. 6 B, anti-TNF-α antibody did not inhibit the IL-15-induced recruitment to the peritoneum. Anti-IL-15 did effectively prevent IL-15-induced lymphocyte traffic, and anti-TNF-α likewise inhibited TNF-α-induced migration, demonstrating functional blocking by these antibodies. Thus, in this in vivo model, IL-15 appears to alter C D 4 4 -mediated homing patterns independent of TNF-α, consistent with our in vitro results.

Discussion

A variety of glycoprotein adhesion receptors primarily belonging to the immunoglobulin or selectin gene families are regulated on endothelium by cytokines or other inflammatory stimuli: E-selectin expression is induced on a variety...
of ECs stimulated with inflammatory agents such as TNF-α, IL-1, or bacterial LPS; VCAM-1 can be induced by IL-1, TNF-α, and IL-4; and levels of ICAM-1 have also been shown to be influenced by cytokines on a variety of ECs (31–33). We have recently added another class of molecule, the glycosaminoglycan hyaluronan, to the list of endothelial adhesion receptors that can be regulated in vitro, and have demonstrated that such elevated HA expression results in enhanced CD44-dependent primary adhesion interactions with lymphocytes (4). Thus, proinflammatory stimuli exert some of their effects by regulating the adhesion and thus recruitment of leukocytes to inflamed sites. IL-15, to our knowledge, has not been demonstrated previously to alter endothelial adhesion molecule expression. These studies show that, although adhesion glycoproteins generally do not appear to be induced by IL-15, the expression level of HA is increased to levels equivalent to that induced by other proinflammatory stimuli (Fig. 1). Given the evidence suggesting a role for the CD44/HA interaction in activated T cell recruitment during immune and autoimmune responses (1–3, 5), the selective upregulation of HA suggested a discrete function for IL-15 in the recruitment of activated T cells.

The role of cytokines in influencing T cell recruitment is complex and incompletely understood, but can potentially occur directly through the parietal peritoneum and/or through the serosal surfaces of any of the visceral organs contained within the peritoneum. Regardless, the high degree of specificity of the responsiveness suggests a role for CD44 in the recruitment of activated T cells through a CD44-mediated pathway.

The functional activities ascribed to IL-15 have been described as broadly analogous to those of IL-2 (for review see reference 15). However, IL-15, but not IL-2, has been shown to have a protective role against apoptosis in non-lymphoid and lymphoid cells (10), and IL-15 has an effect on mast cells through an apparently entirely unique receptor unrelated to IL-2R components (28). In addition, it has recently been described that IL-15 induces the production of macrophages of another key proinflammatory cytokine, TNF-α, although IL-2 was also demonstrated to have a lesser effect (29). The role we have described for IL-15 on ECs adds a further distinct bioactivity that appears to be completely independent of IL-2 and also independent of TNF-α. Analysis of mRNA expression shows no detectable levels of IL-2Rα message in any of the murine ECs.
tested (Fig. 2). This is in agreement with previous reports for human endothelium (12, 16), and is consistent with the lack of an effect of IL-2 on endothelial HA expression (Fig. 1). In addition, IL-2 had no effect on T cell recruitment in vivo (Fig. 4), and therefore also does not appear to operate through secondary cell types and/or cytokines that would support T cell recruitment in this model. These observations bring a functional relevance to the expression of IL-15Rα on ECs, and do so in such a way as to further accentuate its position in pathways of T cell function.

It is of interest that although all endothelial sources examined express IL-15Rα message as well as the coreceptor chains IL-2Rγ and IL-2Rβ (Fig. 2), only a subset of these responded to IL-15 with increased HA expression (Fig. 1). Although it is possible that the level of message expression does not reflect the protein products for these chains, the evidence is also consistent with the possibility that IL-15Rα expression alone is not sufficient for this response, and that downstream signaling mechanisms determine the responsiveness of particular ECs to HA production. These observations will require further investigation.

The studies presented here add the induction of EC adhesion receptors governing the initial phase of T cell adhesion to the list of effector functions coordinated by IL-15, and thus extend this cytokine's influence to the endothelial luminal surface. Recently, IL-15 has been shown to enhance the transmigration of T cells through endothelium, although the mechanism was not clarified (30). Thus, it is attractive to suggest that under inflammatory conditions perivascular tissues and endothelium produce an IL-15 chemotactic gradient that induces endothelial HA production, thereby promoting adhesion and subsequent coordinated migration through the endothelium. Since IL-15 clearly has been shown to be a potent chemoattractant for T cells (6, 36, 37), this may further result in the migration of T cells towards the origin of the stimulus within the tissues proper. IL-15 has been shown to protect activated T cells from apoptosis (9, 38), and in particular has antiapoptotic effects on Fas-mediated death of activated T and B cells, as well as additional cell types in vivo (10). This suggests that IL-15 may prolong the survival of activated T cells under inflammatory states, favoring the execution of their effector functions. Recent observations that IL-15 selectively stimulates a CD44+ CD8α T cell population in vivo and in vitro further supports a role for this cytokine in memory/effector T cell function (39) and is consistent with the evidence presented here. Therefore, IL-15 has the capacity to support multiple events in the life cycle of an effector T cell, beginning with its initial attachment to endothelium during extravasation, as demonstrated here, followed by migration through the vascular barrier and within tissues, and finally enhancement of survival within appropriate sites of antigenic challenge.

Although IL-15 and its various activities have been implicated in the pathogenesis of rheumatoid arthritis (13, 29) and may also play a prominent role in other chronic autoimmune diseases (40, 41), another cytokine thought to be key in the pathogenesis of rheumatoid arthritis is TNF-α. Approaches directed at inhibiting the effects of TNF-α have in fact shown significant therapeutic promise (42, 43). A significant relationship between IL-15 and TNF-α has been demonstrated, in that IL-15 was observed to induce TNF-α production from T cells as well as secondarily from macrophages in a contact-dependent fashion, suggesting that IL-15 acts upstream of TNF-α during rheumatoid arthritis (29). Since both TNF-α and IL-15 induce endothelial HA expression, and both can be produced by ECs, it was of interest to examine whether these cytokines acted coordinately or independently to achieve increased HA levels. The presence of antibody to either cytokine in culture had no effect on the ability of the other to induce HA expression, suggesting that these cytokines act independently at the receptor level and can each have their effects directly on ECs (Fig. 6 A). Moreover, administration of anti-TNF-α antibody in vivo had no effect on the ability of IL-15 to support T cell recruitment into the inflamed peritoneum (Fig. 6 B). This further suggests that even in the presence of additional resident peritoneal cells, such as macrophages, which may be induced by IL-15 to secrete TNF-α, it is not required for the CD44-mediated recruitment of T cells in response to IL-15. Thus, although TNF-α may frequently be a final mediator of inflammatory responses whose production is influenced by IL-15, the evidence presented here suggests that IL-15 has a more direct effect on endothelium itself in T cell extravasation.

In summary, these studies establish a unique function for IL-15 in affecting pathways of activated T cell recruitment to an inflamed site by directly inducing endothelial HA expression, which allows activated T cells to bind via activated CD44. The results reinforce the key role that IL-15 plays throughout multiple stages of T cell effector function, and helps to tie the expression of IL-15 and its receptor on endothelium to the central theme of IL-15 in T cell-mediated immune and autoimmune responses.

We thank Maria Kosfiszer for technical assistance, and Dr. Vinay Kumar for helpful discussions.

This work was supported by grants from the National Institutes of Health (R01 CA57571 and HL56746) and the Arthritis Foundation. M.H. Siegelman is an Established Investigator of the American Heart Association.

Address correspondence to Mark Siegelman, Department of Pathology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9072. Phone: 214-648-4121; Fax: 214-648-4070; E-mail: siegelman@utsw.swmed.edu

Submitted: 27 January 1999 Revised: 26 April 1999 Accepted: 10 May 1999
References

1. DeGrendele, H.C., P. Estess, L.J. Picker and M.H. Siegelman. 1996. Cloning and characterization of a novel anabolic cytokine for skeletal muscle. J. Cell. Physiol. 160:5654–5660.

2. Suzuki, H., T.M. Kundig, C. Furlonger, A. Wakeham, E.C. Butcher, H.G. Thiele, and A. Hamann. 1991. Expression of murine lymphocyte-endothelial cell interaction mechanisms by SV-40-transformed mouse endothelial cell lines: novel mechanisms mediating basal binding, and alpha 4-integrin-dependent cytokine-induced adhesion. Exp. Cell Res. 197:259–267.

3. Ager, A. 1987. Isolation and culture of high endothelial cells from rat lymph nodes. J. Cell Biol. 107:133–144.

4. Aruffo, A., I. Stamenkovic, C.B. Underhill, and M. Edidin. 1990. Monoclonal antibodies to a novel murine lymphocyte activation antigen (MALA-2). J. Immunol. 144:521–525.

5. Harder, R., H. Ulrich, A. Kanash, B. Schutt, A. Duijvestijn, E.C. Butcher, H.G. Thiele, and A. Hamann. 1991. Dissection of murine lymphocyte-endothelial cell interaction mechanisms by SV-40-transformed mouse endothelial cell lines: novel mechanisms mediating basal binding, and alpha 4-integrin-dependent cytokine-induced adhesion. Exp. Cell Res. 197:259–267.

6. Miyake, K., K.L. Medina, S. Hayashi, S. Ono, T. Hamaoka, and H.A. Erlich. 1986. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA DNA with allele-specific oligonucleotide probes. Nature 324:163–166.

7. Suzuki, H., T.M. Kundig, C. Furlonger, A. Wakeham, E.C. Butcher, H.G. Thiele, and A. Hamann. 1991. Dissection of murine lymphocyte-endothelial cell interaction mechanisms by SV-40-transformed mouse endothelial cell lines: novel mechanisms mediating basal binding, and alpha 4-integrin-dependent cytokine-induced adhesion. Exp. Cell Res. 197:259–267.

8. Saki, R.K., T.L. Bugawan, G.T. Horn, K.B. Mullis, and H.A. Erlich. 1986. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA DNA with allele-specific oligonucleotide probes. Nature 324:163–166.
33. Carlos, T.M., and J.M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. Blood. 84:2068–2101.
34. Dinarello, C.A. 1994. To Sheldon M. Wolff, as we commemorate the 10th anniversary of the clonings of IL-1 alpha and IL-1 beta. Eur. Cytokine Netw. 5:513–516.
35. Colotta, F., F. Re, M. Muzio, R. Bertini, N. Polentarutti, M. Sironi, J.G. Giri, S.K. Dower, J.E. Sims, and A. Mantovani. 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 261:472–475.
36. Giri, J.G., D.M. Anderson, S. Kumaki, L.S. Park, K.H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukocyte Biol. 57:763–766.
37. Wilkinson, P.C., and F.Y. Liew. 1995. Chemoattraction of human blood T lymphocytes by interleukin-15. J. Exp. Med. 181:1255–1259.
38. Akbar, A.N., N.J. Borthwick, R.G. Wickremasinghe, P. Panayiotidis, D. Pilling, M. Bofill, S. Krajewski, J.C. Reed, and M. Salmon. 1996. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26:294–299.
39. Zhang, X.H., S.Q. Sun, I.K. Hwang, D.F. Tough, and J. Sprent. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 8:591–599.
40. Agostini, C., L. Trentin, M. Facco, R. Sancetta, A. Cerutti, C. Tassinari, L. Cimarostro, F. Adami, A. Cipriani, R. Zambello, and G. Semenzato. 1996. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J. Immunol. 157:910–918.
41. Kirman, I., and O.H. Nielsen. 1996. Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am. J. Gastroenterol. 91:1789–1794.
42. Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. MacFarlane, and H. Bijl. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1105–1110.
43. Elliott, M.J., R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Bijl, and J.N. Woody. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 344:1125–1127.